Neuronanomedicine for Alzheimer's and Parkinson's disease: Current progress and a guide to improve clinical translation

Neuronanomedicine is an emerging multidisciplinary field that aims to create innovative nanotechnologies to treat major neurodegenerative disorders, such as Alzheimer's (AD) and Parkinson's disease (PD). A key component of neuronanomedicine are nanoparticles, which can improve drug properties and demonstrate enhanced safety and delivery across the blood-brain barrier, a major improvement on existing therapeutic approaches. In this review, we critically analyze the latest nanoparticle-based strategies to modify underlying disease pathology to slow or halt AD/PD progression. We find that a major roadblock for neuronanomedicine translation to date is a poor understanding of how nanoparticles interact with biological systems (i.e., bio-nano interactions), which is partly due to inconsistent reporting in published works. Accordingly, this review makes a set of specific recommendations to help guide researchers to harness the unique properties of nanoparticles and thus realise breakthrough treatments for AD/PD.

Automated summary

Neuronanomedicine is a multidisciplinary field that aims to develop innovative nanotechnologies for the treatment of neurodegenerative disorders. Nanoparticles are an important component of neuronanomedicine, as they can improve drug properties and enhance safety and delivery across the blood-brain barrier. However, a major challenge for neuronanomedicine translation is the poor understanding of bio-nano interactions, partly due to inconsistent reporting in published works. This review provides specific recommendations to guide researchers in harnessing the unique properties of nanoparticles for breakthrough treatments of Alzheimer's and Parkinson's disease.